Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

NCT00430963 is registered in ClinicalTrials.gov with Merz Pharmaceuticals GmbH as lead sponsor.

NCT NCT00430963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00430963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines
Lead sponsor
Merz Pharmaceuticals GmbH
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2006
Completion date
November 30, 2007
Enrollment
256 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines